Apotex Pays Out Over US Price-Fixing Claims

Deal Over Pravastatin Includes $24.1m Fine And Deferred Prosecution Agreement

Apotex has agreed to pay a $24.1m fine and enter into a deferred prosecution agreement to resolve US price-fixing claims over the cholesterol-lowering drug pravastatin.

Apotex
Apotex has settled US price-fixing allegations over pravastatin • Source: Shutterstock

Apotex has agreed to pay a $24.1m fine and has entered into a deferred prosecution agreement with the US Department of Justice to resolve price-fixing claims over the pravastatin cholesterol-lowering treatment, in the latest development arising out of ongoing generic pricing investigations in the US.

“Apotex Corp. has reached a resolution with the DoJ’s antitrust division concerning the department’s years-long antitrust investigation into the US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar

 
• By 

Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.

UPC Imposes Wide Cross-Border Injunction On Zentiva In Ofev Patent Clash

 
• By 

The UPC Court of Appeal has signaled that in pharma disputes, being ready to launch can be as risky as actually launching. In a major setback for Zentiva, the court ruled that completing certain steps well before patent expiry amounted to “setting the stage” for infringement.

UK Decision Opens Up Competition On Forxiga

 
• By 

Generic dapagliflozin rivals to AstraZeneca’s Forxiga are now free to hit the UK market after the country’s Supreme Court lifted the final barrier preventing launch, allowing off-patent firms access to a market worth hundreds of millions of pounds annually.

Sandoz Rushes To Fill Gap After German Court Revokes Xarelto Patent

 
• By 

Germany’s Federal Patent Court has invalidated Bayer’s key patent covering once-daily use of Xarelto (rivaroxaban), paving the way for Sandoz to launch a generic version. Bayer is considering an appeal.

More from Generics Bulletin

Cingulate Installs Interim Leadership After CEO Put On Administrative Leave

 
• By 

Shortly after filing its lead candidate for ADHD through the FDA’s 505(b)(2) hybrid new drug application pathway, Cingulate has appointed interim leadership after placing chairman and CEO Shane Schaffer on administrative leave over legal matters unrelated to the company.

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar

 
• By 

Roche and its Genentech subsidiary have sued Shanghai Henlius Biotech and commercialization partner Organon in the US, alleging infringement of 24 patents covering Perjeta (pertuzumab). The litigation follows Roche’s recent disclosure that biosimilars to Perjeta could launch as soon as 2026.

Accord Takes On Ustekinumab Rivals In US With Steepest Discount Yet

 
• By 

Boasting the “lowest WAC price among branded biosimilars to Stelara”, Accord BioPharma has launched its Imuldosa version of ustekinumab in the US at a 92% discount to the blockbuster immunology brand.